Thursday 12 November 2026 Export INCY’s income statement to Excel — free account

Incyte Corporation

INCY

Healthcare Biotechnology

Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024.

Revenue: +14.0%
EPS: −277.9%
Free cash flow: −233.0%
Total debt: −10.5%

Quarter to September 2026, against a year earlier

121.89 0.38 −0.31%

Follow INCY

Alert me

Market cap: $24.9B
P/E: 58.1×
Fwd P/E: 57.3×
Dividend yield: —
F-score: 9/9
ROIC: 21.6%
Net debt / EBITDA: −2.2×
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Incyte Corporation (INCY) P/B ratio

Alert me on P/B ratio

As of 12 November 2026, Incyte Corporation (INCY) trades at a P/B ratio of 4.4×. Over the past ten years it has ranged from 0.0× (June 2015) to 426× (September 2015); the current reading is higher than 40% of that period. That is above the Biotechnology industry median of 2.2× and above the Healthcare sector median of 2.3×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/INCY/pb-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Incyte Corporation P/B ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/INCY/metrics/pb-ratio">Incyte Corporation (INCY) P/B ratio — stockrow.com</a></p>

Period	P/B ratio	Change
FY2025	3.7×	(10.08%)
FY2024	4.1×	47.13%
FY2023	2.8×	(30.21%)
FY2022	4.0×	(5.83%)
FY2021	4.3×	(40.92%)
FY2020	7.3×	0.58%
FY2019	7.2×	2.99%
FY2018	7.0×	(44.60%)
FY2017	12.7×	(72.38%)
FY2016	45.8×	(59.73%)

Period	P/B ratio	Change
Sep 2026	4.4×	22.08%
Jun 2026	3.6×	7.30%
Mar 2026	3.3×	(10.57%)
Dec 2025	3.7×	4.57%
43 more quarters	Free account

Against its own ten years

Low 0.0× High 426×

Ten-year median 6.2×

Current reading's percentile 39

Company	P/B ratio
BNTX BioNTech SE Sponsored ADR compare	1.0×
JAZZ Jazz Pharmaceuticals PLC compare	3.7×
INCY Incyte Corporation	4.4×
GMAB Genmab A/S Sponsored ADR compare	5.0×
ALNY Alnylam Pharmaceuticals, Inc. compare	5.8×
ROIV Roivant Sciences Ltd. compare	6.3×
EXEL Exelixis, Inc. compare	9.4×
ASND Ascendis Pharma A/S compare	10.3×
INSM Insmed, Inc. compare	35.5×
Biotechnology industry median	2.2×
Healthcare sector median	2.3×
Market median	1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

Incyte Corporation (INCY) P/B ratio

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on INCY

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on INCY

Stockrow Weekly